Melphalan
Alkeran · Alkylator
SIADH in high-dose myeloma conditioning; renally cleared.
Alkylating agent (nitrogen mustard)
Leukeran · CLB
Alkylating agent (nitrogen mustard) · approved 1957 · 3 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
Oral aromatic nitrogen-mustard alkylator with minimal direct nephrotoxicity; the notable renal-relevant effect is rare drug-associated SIADH/hyponatremia.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Chlorambucil has minimal direct nephrotoxicity. Drug-associated SIADH with hyponatremia is reported only rarely, in isolated case reports; tumor lysis is uncommon given its indolent-disease indications and gradual cytoreduction. No reliable incidence figure exists.Source: Wagner et al., Ann Hematol 1999 (case-level SIADH); incidence not quantified
Hyponatremia, when reported, has occurred during ongoing dosing including at low doses, with variable timing.
Distilled from: “Hyponatremia, when reported, has occurred during ongoing dosing, including with low doses; timing is variable.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Inappropriate water retention at the collecting duct — high-dose cyclophosphamide.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Aromatic nitrogen-mustard alkylating agent that forms reactive ethyleniminium intermediates and crosslinks DNA, impairing replication and transcription in proliferating lymphoid cells and inducing apoptosis.
Distal Tubule / Collecting Duct
Fine-tuning of Na, K, Mg, acid & water
Class-level context for the major non-renal toxicities of the Alkylating agent (nitrogen mustard) class.
Ophthalmic
Keratopathy, uveitis, retinopathy
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
3 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Quoted verbatim from this agent's current FDA label (Jan 2025) — not paraphrased or interpreted. Full label on DailyMed .
Boxed warning
WARNING LEUKERAN (chlorambucil) can severely suppress bone marrow function. Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility (see WARNINGS and PRECAUTIONS).
Kidney rows of the label's dosage tables
None of the newest openFDA labels for this product carries a dosage table. The label's prose can still give kidney instructions.
Everything below is FAERS — adverse events someone chose to report, about 3,932 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
930 of 3,932 reports
Reported with hospitalization
1,636 of 3,932 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 1,221 of the 3,932 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Chlorambucil sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Alkeran · Alkylator
SIADH in high-dose myeloma conditioning; renally cleared.
Temodar · Alkylator
Occasional SIADH; generally renally well tolerated.
Velban · Vinca alkaloid
SIADH and rare Raynaud/vascular events.
Oncovin · Vinca alkaloid
SIADH → hyponatremia.
Navelbine · Vinca alkaloid
SIADH reports.
Erivedge · Hedgehog (SMO) inhibitor
Muscle spasms; hyponatremia reported.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Chlorambucil’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Chlorambucil; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 87 clinical records among all 275 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.